Literature DB >> 27648130

Silencing of CXCR2 and CXCR7 protects against esophageal cancer.

Kai Wu1, Lingling Cui2, Yang Yang1, Jia Zhao1, Dengyan Zhu1, Donglei Liu1, Chunyang Zhang1, Yu Qi1, Xiangnan Li1, Weihao Li1, Song Zhao1.   

Abstract

This study was aimed to investigate the functional roles of cytokine receptor (CXCR) CXCR2 and CXCR7 in esophageal cancer (EC). Specific small interfering RNAs (siRNA) against CXCR2 and CXCR7 were transfected into EC cell lines TE-1, EC9706, and EC109 cells. Expression of CXCR2 and CXCR7 was validated, along with cell viability, chemotaxis, apoptosis rate, and ERK1/2 pathways associated protein after transfection. Moreover, EC9706 cells treated with or without CXCR2/7 siRNA were injected into athymic nude mice. Tumor volumes were measured. Besides, immunohistochemical (IHC) staining was performed to investigate the expression of CXCR2/7 in adjacent normal tissues and tumor tissues from esophageal squamous cell carcinoma (ESCC) patients. Also, the associations between CXCR2/7 expression and clinicopathological features and progression were explored. The mRNA levels of CXCR2 and CXCR7 were significantly reduced after transfection. Silencing of CXCR2 and CXCR7 statistically decreased cell viability and chemotaxis, and increased apoptotic rate. Cells invasion was significantly reduced by silencing of CXCR2, however, no significance was found in silencing of CXCR7. The protein levels of pERK1/2 were significantly decreased by silencing of CXCR2 and CXCR7. Besides, silencing of CXCR2 and CXCR7 significantly reduced tumor growth in vivo, and associated with clinicopathological features and progression. Silencing of CXCR2 and CXCR7 protects against EC by inhibiting cell growth and chemotaxis, and inducing apoptosis though ERK1/2 pathways. Silencing of CXCR2 and CXCR7 has potentially therapeutic target for EC.

Entities:  

Keywords:  CXCR2; CXCR7; Esophageal cancer; SiRNA; clinicopathological features; progression

Year:  2016        PMID: 27648130      PMCID: PMC5009392     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  38 in total

1.  Immunohistochemical analysis of tissue microarrays.

Authors:  Ronald Simon; Martina Mirlacher; Guido Sauter
Journal:  Methods Mol Biol       Date:  2010

2.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 3.  The chemokine system and cancer.

Authors:  Frances R Balkwill
Journal:  J Pathol       Date:  2011-11-23       Impact factor: 7.996

4.  Expression of the chemokine receptors CXCR1 and CXCR2 on granulocytes in human endotoxemia and tuberculosis: involvement of the p38 mitogen-activated protein kinase pathway.

Authors:  N P Juffermans; P E Dekkers; M P Peppelenbosch; P Speelman; S J van Deventer; T van Der Poll
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

5.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

6.  Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Authors:  Seema Singh; Anguraj Sadanandam; Kalyan C Nannuru; Michelle L Varney; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

7.  Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells.

Authors:  Ke Zheng; Hong-Yuan Li; Xin-Liang Su; Xiao-Yi Wang; Tian Tian; Fan Li; Guo-Sheng Ren
Journal:  J Exp Clin Cancer Res       Date:  2010-04-11

8.  The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour.

Authors:  Syed A Khurram; Lynne Bingle; Brenka M McCabe; Paula M Farthing; Simon A Whawell
Journal:  J Oral Pathol Med       Date:  2014-06-26       Impact factor: 4.253

9.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

10.  Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo.

Authors:  J Meijer; J Ogink; E Roos
Journal:  Br J Cancer       Date:  2008-10-14       Impact factor: 7.640

View more
  12 in total

Review 1.  Chemokines and their receptors as biomarkers in esophageal cancer.

Authors:  Masakazu Goto; Mingyao Liu
Journal:  Esophagus       Date:  2019-11-26       Impact factor: 4.230

2.  IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.

Authors:  Y Qiao; C Zhang; A Li; D Wang; Z Luo; Y Ping; B Zhou; S Liu; H Li; D Yue; Z Zhang; X Chen; Z Shen; J Lian; Y Li; S Wang; F Li; L Huang; L Wang; B Zhang; J Yu; Z Qin; Y Zhang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

3.  Prognostic Impact of CXCR7 and CXCL12 Expression in Patients with Esophageal Adenocarcinoma.

Authors:  Masakazu Goto; Yukiko Shibahara; Cristina Baciu; Frances Allison; Jonathan C Yeung; Gail E Darling; Mingyao Liu
Journal:  Ann Surg Oncol       Date:  2021-03-11       Impact factor: 5.344

4.  Gene function analysis and underlying mechanism of esophagus cancer based on microarray gene expression profiling.

Authors:  Ying Yue; Mengjia Song; Yamin Qiao; Pupu Li; Yiqiang Yuan; Jingyao Lian; Suying Wang; Yi Zhang
Journal:  Oncotarget       Date:  2017-10-30

5.  Systematic review and meta-analysis of the prognostic value of CXCR2 in solid tumor patients.

Authors:  Yong Yang; Baoyang Luo; Yong An; Han Sun; Huihua Cai; Donglin Sun
Journal:  Oncotarget       Date:  2017-11-03

Review 6.  Functions and mechanisms of chemokine receptor 7 in tumors of the digestive system.

Authors:  Qi Xin; Quan Sun; Chuan-Shan Zhang; Qin Zhang; Chun-Jun Li
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

7.  CXCR7, a Prognostic Biomarker in Cervical Squamous Cell Carcinoma, May Be a Screening Index for Treatment Options at Stages IB1 and IIA1.

Authors:  Danyang Zhao; Wenban Qin; Chuanxiang Zhao; Jianxiong Long; Mujun Li
Journal:  Cancer Manag Res       Date:  2019-12-09       Impact factor: 3.989

Review 8.  Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy.

Authors:  Ajaz A Bhat; Sabah Nisar; Selma Maacha; Tatiana Correa Carneiro-Lobo; Sabah Akhtar; Kodappully Sivaraman Siveen; Nissar A Wani; Arshi Rizwan; Puneet Bagga; Mayank Singh; Ravinder Reddy; Shahab Uddin; Jean-Charles Grivel; Gyan Chand; Michael P Frenneaux; Mushtaq A Siddiqi; Davide Bedognetti; Wael El-Rifai; Muzafar A Macha; Mohammad Haris
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

9.  Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.

Authors:  Chang-Shuo Huang; Shye-Jye Tang; Mei-Hsuan Lee; Chien-Chih Chang Wang; Guang-Huan Sun; Kuang-Hui Sun
Journal:  J Cell Mol Med       Date:  2018-09-24       Impact factor: 5.310

Review 10.  Advances in CXCR7 Modulators.

Authors:  Nicole Lounsbury
Journal:  Pharmaceuticals (Basel)       Date:  2020-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.